Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 5/20 | 0.50 |
| ▸ | HTR1A | P08908 | 1/20 | 0.50 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.50 |
| ▸ | HTR2C | P28335 | 4/20 | 0.46 |
| ▸ | DRD2 | P14416 | 3/20 | 0.46 |
| ▸ | HTR2B | P41595 | 3/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.46 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HTR7 | P34969 | 1/20 | 0.42 |
| ▸ | HTR6 | P50406 | 1/20 | 0.42 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL5660938 | 0.93 | HTR2A (0.49) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Fumaric Acid SCHEMBL5660934 | 0.93 | HTR2A (0.49) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL5252123 | 0.85 | HTR1A (0.48) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL5658151 | 0.85 | HTR2A (0.48) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| SCHEMBL5660124 | 0.85 | HTR2A (0.67) | HTR2AHTR1ATMEM97HTR7ACHE | |
| Fumaric Acid SCHEMBL5656373 | 0.84 | HTR2A (0.52) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Fumaric Acid SCHEMBL5656376 | 0.84 | HTR2A (0.52) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Hydrochloric Acid SCHEMBL5657727 | 0.84 | HTR2A (0.66) | HTR2AHTR1ATMEM97HTR7ACHE | |
| SCHEMBL5248887 | 0.82 | HTR2A (0.75) | HTR2AHTR1ATMEM97HTR2CDRD2 | |
| Fumaric Acid SCHEMBL5657213 | 0.81 | HTR2A (0.49) | HTR2AHTR1ATMEM97HTR2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166617-B2 | Cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2007-01-23 | — | — | US | disclosed |
| US-20030212094-A1 | Novel cyclic amide derivatives | MITSUBISHI PHARMA CORPORATION (JP) | 2003-11-13 | — | — | US | disclosed |
| EP-1260512-A1 | NOVEL CYCLIC AMIDE DERIVATIVES | Mitsubishi Pharma Corporation (JP) | 2002-11-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030212094-A1 | Novel cyclic amide derivatives | SIGMAR1, OPRM1, OPRD1 | HTR2A 153/4885HTR1A 79/4885TMEM97 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.